DE69431834D1 - Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung - Google Patents
Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendungInfo
- Publication number
- DE69431834D1 DE69431834D1 DE69431834T DE69431834T DE69431834D1 DE 69431834 D1 DE69431834 D1 DE 69431834D1 DE 69431834 T DE69431834 T DE 69431834T DE 69431834 T DE69431834 T DE 69431834T DE 69431834 D1 DE69431834 D1 DE 69431834D1
- Authority
- DE
- Germany
- Prior art keywords
- nucleic acid
- acid molecule
- mage
- tumor
- repellation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/037,230 US6235525B1 (en) | 1991-05-23 | 1993-03-26 | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
PCT/US1994/002877 WO1994023031A1 (en) | 1993-03-26 | 1994-03-17 | Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69431834D1 true DE69431834D1 (de) | 2003-01-16 |
DE69431834T2 DE69431834T2 (de) | 2003-09-18 |
Family
ID=21893179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69431834T Expired - Lifetime DE69431834T2 (de) | 1993-03-26 | 1994-03-17 | Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung |
Country Status (15)
Country | Link |
---|---|
US (6) | US6235525B1 (de) |
EP (1) | EP0690915B1 (de) |
JP (1) | JP3594307B2 (de) |
KR (1) | KR100288749B1 (de) |
CN (1) | CN1110556C (de) |
AT (1) | ATE229072T1 (de) |
AU (1) | AU685790B2 (de) |
CA (1) | CA2159098C (de) |
DE (1) | DE69431834T2 (de) |
FI (1) | FI954536A (de) |
NO (1) | NO953699L (de) |
NZ (1) | NZ263693A (de) |
TW (1) | TW432111B (de) |
WO (1) | WO1994023031A1 (de) |
ZA (1) | ZA941644B (de) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE40089E1 (en) * | 1991-05-23 | 2008-02-19 | Ludwig Institute For Cancer Research | Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor |
US5925729A (en) * | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US6060257A (en) * | 1994-06-03 | 2000-05-09 | Ludwig Institute For Cancer Research | Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof |
US5587289A (en) * | 1995-03-14 | 1996-12-24 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof |
WO1997013858A2 (en) * | 1995-10-12 | 1997-04-17 | Chiron Corporation | Baboon mage-3 homologs, dna encoding the homologs, and a process for their use |
UY24367A1 (es) * | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
RS50101B (sr) | 1996-02-24 | 2009-01-22 | Boehringer Ingelheim International Gmbh., | Farmaceutski preparati za imunomodulaciju |
FR2746110B1 (fr) * | 1996-03-14 | 1998-04-17 | Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants | |
US6027924A (en) * | 1997-04-25 | 2000-02-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof |
US5965535A (en) | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US6716809B1 (en) | 1997-09-12 | 2004-04-06 | Ludwig Institute For Cancer Research | Mage-A3 peptides presented by HLA class molecules |
JP4768121B2 (ja) | 1998-02-05 | 2011-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Mageファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用 |
US6446109B2 (en) * | 1998-06-29 | 2002-09-03 | Sun Microsystems, Inc. | Application computing environment |
US20080318890A1 (en) * | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7960540B2 (en) * | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US20080318889A1 (en) * | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
JP2002541264A (ja) * | 1999-04-08 | 2002-12-03 | ユーエイビー・リサーチ・ファウンデーション | 冨gオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法 |
US8114850B2 (en) * | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
IT1312568B1 (it) * | 1999-05-21 | 2002-04-22 | Genera Spa | Peptidi immunogenici e loro uso. |
AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
JP3603138B2 (ja) * | 2000-02-18 | 2004-12-22 | 独立行政法人理化学研究所 | 細胞死抑制タンパク質 |
AU5810201A (en) | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
EP1294905A1 (de) * | 2000-06-26 | 2003-03-26 | SmithKline Beecham Biologics SA | Triple-fusionsprotein von ubiquitin, die zwischen thioredoxin und ein polypeptid von interesse fusioniert ist |
WO2002083945A2 (en) | 2001-04-12 | 2002-10-24 | Imperial College Innovations Limited | Diagnosis and treatment of cancer: i |
US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
AU2004280608B2 (en) * | 2002-04-09 | 2012-04-05 | Sanofi Pasteur, Inc. | Modified CEA/B7 vector |
CA2510238A1 (en) * | 2002-10-22 | 2004-05-06 | Sanofi Pasteur Limited | Cancer treatment using vaccine and high-dose cytokine |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
US20070154889A1 (en) * | 2004-06-25 | 2007-07-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
GB0700284D0 (en) * | 2007-01-08 | 2007-02-14 | Glaxosmithkline Biolog Sa | Combination therapy |
WO2009061996A2 (en) | 2007-11-07 | 2009-05-14 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
US20090131351A1 (en) * | 2007-11-16 | 2009-05-21 | Antisoma Research Limited | Methods, compositions, and kits for modulating tumor cell proliferation |
MX2010010034A (es) | 2008-03-14 | 2010-12-06 | Sanofi Pasteur Biologics Co | Vacunas de flavivirus defectuosas en replicacion y vectores de vacunas. |
KR101958753B1 (ko) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 cd27에 결합하는 항체 및 이의 용도 |
SI3473267T1 (sl) | 2011-05-24 | 2022-01-31 | BioNTech SE | Individualizirana cepiva za rak |
GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
EP3417874A1 (de) | 2012-11-28 | 2018-12-26 | BioNTech RNA Pharmaceuticals GmbH | Individualisierte impfstoffe gegen krebs |
WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
KR101923326B1 (ko) | 2014-06-06 | 2018-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 |
WO2016040682A1 (en) | 2014-09-10 | 2016-03-17 | Genentech, Inc. | Immunogenic mutant peptide screening platform |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
WO2016094309A1 (en) | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
MY188049A (en) | 2015-05-29 | 2021-11-12 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
GB201519340D0 (en) | 2015-11-02 | 2015-12-16 | Cambridge Entpr Ltd | Methods of T-lymphocyte expansion |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
EP3377532B1 (de) | 2015-11-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antikörper gegen glucocorticoidinduzierten tumornekrosefaktorrezeptor (gitr) und verwendungen davon |
CN109071665B (zh) | 2016-04-18 | 2022-11-01 | 塞德斯医疗公司 | 结合人cd40的激动性抗体及其用途 |
GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
LT3565579T (lt) | 2017-01-05 | 2023-09-11 | Kahr Medical Ltd. | Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai |
CA3047708A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirpalpha-41bbl fusion protein and methods of use thereof |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
WO2019006003A1 (en) | 2017-06-27 | 2019-01-03 | The Trustees Of Princeton University | COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY |
GB201713078D0 (en) | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
CN111836635A (zh) | 2018-01-26 | 2020-10-27 | 剑桥企业有限公司 | 肽交换蛋白 |
WO2020012486A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
WO2020041662A1 (en) | 2018-08-24 | 2020-02-27 | The Trustees Of Princeton University | Immunotherapy with metabolic enzyme expression |
GB201820444D0 (en) | 2018-12-14 | 2019-01-30 | Adaptimmune Ltd | Marker for T cell expansion |
KR20220044284A (ko) | 2019-07-11 | 2022-04-07 | 카 메디컬 리미티드 | 이종이량체 및 이의 사용방법 |
GB201911954D0 (en) | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Lentiviral transduction methods |
US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
WO2021137230A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61104788A (ja) * | 1984-10-26 | 1986-05-23 | Teijin Ltd | 核酸塩基配列 |
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
JPH05246889A (ja) * | 1992-03-05 | 1993-09-24 | Seitai Chiyousetsu Kenkyusho:Kk | 制癌方法および制癌剤 |
US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
-
1993
- 1993-03-26 US US08/037,230 patent/US6235525B1/en not_active Expired - Lifetime
-
1994
- 1994-03-09 ZA ZA941644A patent/ZA941644B/xx unknown
- 1994-03-17 DE DE69431834T patent/DE69431834T2/de not_active Expired - Lifetime
- 1994-03-17 CA CA002159098A patent/CA2159098C/en not_active Expired - Lifetime
- 1994-03-17 NZ NZ263693A patent/NZ263693A/en not_active IP Right Cessation
- 1994-03-17 JP JP52211494A patent/JP3594307B2/ja not_active Expired - Lifetime
- 1994-03-17 KR KR1019950704143A patent/KR100288749B1/ko not_active IP Right Cessation
- 1994-03-17 AT AT94912246T patent/ATE229072T1/de active
- 1994-03-17 AU AU64475/94A patent/AU685790B2/en not_active Expired
- 1994-03-17 EP EP94912246A patent/EP0690915B1/de not_active Expired - Lifetime
- 1994-03-17 WO PCT/US1994/002877 patent/WO1994023031A1/en active IP Right Grant
- 1994-03-26 CN CN94103919A patent/CN1110556C/zh not_active Expired - Lifetime
- 1994-07-18 TW TW083106555A patent/TW432111B/zh not_active IP Right Cessation
-
1995
- 1995-09-20 NO NO953699A patent/NO953699L/no not_active Application Discontinuation
- 1995-09-25 FI FI954536A patent/FI954536A/fi unknown
-
1997
- 1997-11-12 US US08/967,727 patent/US6025474A/en not_active Expired - Lifetime
-
1999
- 1999-05-17 US US09/312,464 patent/US6599699B1/en not_active Expired - Lifetime
- 1999-09-23 US US09/404,026 patent/US6565857B1/en not_active Expired - Fee Related
-
2000
- 2000-05-26 US US09/579,197 patent/US6552180B1/en not_active Expired - Fee Related
- 2000-05-31 US US09/583,848 patent/US6946289B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ263693A (en) | 1996-07-26 |
JP3594307B2 (ja) | 2004-11-24 |
CN1093751A (zh) | 1994-10-19 |
US6946289B1 (en) | 2005-09-20 |
US6025474A (en) | 2000-02-15 |
KR100288749B1 (ko) | 2001-05-02 |
CA2159098A1 (en) | 1994-10-13 |
AU6447594A (en) | 1994-10-24 |
ZA941644B (en) | 1994-10-12 |
AU685790B2 (en) | 1998-01-29 |
US6235525B1 (en) | 2001-05-22 |
EP0690915A4 (de) | 1997-11-12 |
CA2159098C (en) | 2003-04-29 |
FI954536A0 (fi) | 1995-09-25 |
US6565857B1 (en) | 2003-05-20 |
ATE229072T1 (de) | 2002-12-15 |
JPH08508402A (ja) | 1996-09-10 |
DE69431834T2 (de) | 2003-09-18 |
US6599699B1 (en) | 2003-07-29 |
EP0690915A1 (de) | 1996-01-10 |
CN1110556C (zh) | 2003-06-04 |
NO953699L (no) | 1995-11-20 |
TW432111B (en) | 2001-05-01 |
FI954536A (fi) | 1995-09-25 |
WO1994023031A1 (en) | 1994-10-13 |
US6552180B1 (en) | 2003-04-22 |
EP0690915B1 (de) | 2002-12-04 |
NO953699D0 (no) | 1995-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69431834D1 (de) | Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung | |
ATE251175T1 (de) | Isoliertes nukleinsäuremolekül, das für den tumorabstossungs-antigenvorläufer dage kodiert und seine verwendung | |
DE69233435D1 (de) | Vorläufer von für tumorabstossung verantwortlichen antigenen, die antigene und deren verwendungen | |
DE69617440D1 (de) | Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen | |
ZA944196B (en) | Isolated peptides which form complexes with MHC molecule HLA-C-clone 10 and uses thereof | |
HUP0103758A2 (hu) | Neurotróf faktorok | |
ATE348632T1 (de) | Prion protein peptide und deren verwendung | |
DK43890A (da) | Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse | |
NZ302821A (en) | isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors | |
NZ332369A (en) | Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof | |
ATE313551T1 (de) | Isoliertes nukleinsäuremolekül, das die tumorabstossungs-antigenvorläufer mage- c1 und mage-c2 kodiert und seine verwendung | |
GR3034725T3 (en) | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy. | |
WO1996009391A3 (en) | Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19 | |
UA66753C2 (en) | Immunostimulator and method for its production | |
EP0446797A3 (en) | Synthetic peptides containing factor viia sequences and their use | |
TW372973B (en) | Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof | |
ATE312847T1 (de) | Anti-ssrp-1 monoklonale antikörper und hybridome zur deren herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |